---
title: "Clonal Hematopoiesis and Trastuzumab-Related Cardiotoxicity in Breast Cancer"
id: "jama-oncology-5-clonal-hematopoiesis-and-risk-of-trastuzumab-related-cardiotoxic-effects"
canonical_url: "https://medichelpline.com/clinical-feed/jama-oncology-5-clonal-hematopoiesis-and-risk-of-trastuzumab-related-cardiotoxic-effects"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "JAMA Oncology"
source_url: "https://jamanetwork.com/journals/jamaoncology/fullarticle/2847154"
published_at: "2026-04-02T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Clonal Hematopoiesis and Trastuzumab-Related Cardiotoxicity in Breast Cancer
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/jama-oncology-5-clonal-hematopoiesis-and-risk-of-trastuzumab-related-cardiotoxic-effects
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** JAMA Oncology
- **Source URL:** [Original Journal Publication](https://jamanetwork.com/journals/jamaoncology/fullarticle/2847154)
- **Published At:** 2026-04-02T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
This analysis of 2 cohort studies and a mouse model examined the association of clonal hematopoiesis of indeterminate potential with cardiotoxic effects in patients with breast cancer receiving trastuzumab.
## Clinical Analysis & Structured Key Points
JAMA Oncology published a clinical update in Oncology on 02 Apr 2026. The item focuses on Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxic Effects. Review the original article for the full source wording and details.
## Related Clinical Research

- [Proprioceptive Neuromuscular Facilitation for Upper-Limb Rehab After Breast Cancer: Systematic Rev](https://medichelpline.com/clinical-feed/pubmed-43064868.md) (DOI: 10.1007/s11912-026-01867-3)
- [hsa‑circ‑0007766 drives breast cancer cell growth and spread via a miR‑1301‑3p/DNMT3B feedback loop](https://medichelpline.com/clinical-feed/pubmed-43059377.md) (DOI: 10.3892/mmr.2026.14078)
- [Circulating immune signatures during pembrolizumab-based neoadjuvant therapy in early triple-negat](https://medichelpline.com/clinical-feed/medrxiv-21-circulating-immune-dynamics-during-neoadjuvant-chemoimmunotherapy-in-early.md)
- [Editorial Note: Retractions linked to Naringenin–MCF-7 study cited in PLOS ONE article](https://medichelpline.com/clinical-feed/plos-one-12-editorial-note-naringenin-impairs-mitochondrial-function-via-ros-to-induce.md)
- [FDA clears Roche’s giredestrant; semaglutide shows efficacy in children with severe obesity](https://medichelpline.com/clinical-feed/stat-news-4-stat-pharmalittle-we-re-reading-about-a-roche-breast-cancer-pill-obesity-drugs.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.